Curis targets full enrollment in PCNSL registrational study within 12–18 months while advancing CLL proof-of-concept (NASDAQ:CRIS)

Earnings Call InsightsCuris targets full enrollment in PCNSL registrational study within 12–18 months while advancing CLL proof-of-conceptMar 19, 2026, 6:03 PM ETCuris, Inc. (CRIS) StockAI-Generated Earnings Calls InsightsCommentsEarnings Call Insights: Curis, Inc. (CRIS) Q4 2025 Management View James Dentzer, President and CEO, stated that "we continue to make steady progress in our TakeAim Lymphoma study in primary CNS lymphoma, one of the most rare and most difficult to treat of theNewsletters for Every ...